Study to Evaluate Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors
- Study Title
- A Study to Evaluate 5 ־¼g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
- Teva Identifier
- XM02-ONC-201 | 2014-001772-55
- ClinicalTrials.gov Identifier
- NCT02190721
- Study Status
- Completed
- Trial Condition(s)
- Neutropenia
- Interventions
- Drug: tbo-filgrastim
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child
- Age Range
- 1 Month to 16 Years
- Trial Duration
- May 12, 2015 - April 4, 2017
- Phase
- Phase 2
